Barclays analyst Emily Field initiated coverage with a Buy rating on PolyPeptide Group AG (PPGN – Research Report) today and set a price target ...

In response to the growing demand for peptide drugs, Cytovance Biologics and PolyPeptide have announced a partnership that combines Cytovance’s expertise in microbial and mammalian expression, process ...

Barclays (LON:BARC) initiated coverage on PolyPeptide Group AG (SIX:PPGN:SW) stock with an Overweight rating and a price target of CHF 40.00. The firm anticipates a return to positive EBITDA for ...

Juan José González, CEO of PolyPeptide: “The large-scale capacity expansion in Malmö allows us to further deepen the long-standing collaboration with an important GLP-1 customer. We are making good ...

Palantir Technologies (NASDAQ:PLTR) has been described as the best pure-play stock in artificial intelligence. The market ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Proteins are fundamental to life. They are involved in virtually every process within our bodies, from catalyzing chemical ...

Incretin-mimetic drugs contribute to dramatic weight loss, but this does not solely mean fat loss. In this article, we ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

AI is poised to revolutionize drug discovery, but uncertainty in developing protectable IP in this emerging field creates a host of potential ...

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...